Dr. Ming-Wei Wang (Director, the National Center for Drug Screening/Chinese National Compound Library and Dean, School of Pharmacy, Fudan University) attended the 7th Board Meeting of Novo Nordisk Hemophilia Research Fund in China (i.e., 2018 Novo Nordisk Hemophilia Research Fund in China Management Committee Meeting) at Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences located in Tianjin on April 20, 2018. Chaired by Academician Sajuan Chen, Director of The National Center for Translational Medicine (Shanghai), the meeting discussed and approved the list of 2018 grant recipients, 2017 financial report and the venue for the 8th Board Meeting (2019). Chinese Board members who attended the meeting also include Drs. Xiaodong Xi (Shanghai Institute of Hematology), Yongqiang Zhao (Department of Hematology, Beijing Union Hospital) and Renchi Yang (Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin), as well as Professor Qiulan Ding (Fund Secretary; Department of Hematology, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiaotong University) and Dr. Yinyin Chen of The National Center for Translational Medicine (Shanghai). Representing Novo Nordisk, Drs. Daniel Brunicardi Tiemmermann (Corporate Vice President of Hemophilia Research), Carsten Ley (Director of Pharmacology), Bo Wiinberg (Director of Hemophilia Biology), Boerge Diderichsen (Former Vice President and External Advisor), Lu Dai (Senior Medical Affairs Manager) as well as Ms. Zhujun Zhang (Medical Advisor) from Novo Nordisk (China) Pharmaceuticals Co., Ltd. were present. Professor Zhijian Xiao, Deputy Director of Institute of Hematology, Chinese Academy of Medical Sciences, made opening remarks at the meeting.